drugset / Trial / NCT00071539

Safety and Efficacy Study to Treat Recurrent Grade 4 Malignant Brain Tumors

NCT00071539 ↗

Phase 2 Completed 56 enrolled Teva Branded Pharmaceutical Products R&D, Inc.
Non-randomizedParallel-groupOpen-labelTreatment

Summary

Immunotoxins can locate tumor cells and kill them without harming normal cells. Immunotoxin therapy may be effective in treating malignant glioma.

Timeline

Start
2003-10
Primary completion
2006-01
Completion
2006-07

Drugs

EvaluationDrugModalityDoseRoute
Subject TP-38 Protein / enzyme biologic 50 ng/ml —
Subject TP-38 Protein / enzyme biologic 100 ng/ml —

Indications